Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Current Deferred Revenue: 2009-2019

Historic Current Deferred Revenue for Avadel Pharmaceuticals (AVDL) over the last 9 years, with Mar 2019 value amounting to $115,000.

  • Avadel Pharmaceuticals' Current Deferred Revenue was N/A to $115,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $115,000, marking a year-over-year change of. This contributed to the annual value of $114,000 for FY2018, which is 94.32% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Current Deferred Revenue of $115,000 as of Q1 2019, which was up 0.88% from $114,000 recorded in Q4 2018.
  • Avadel Pharmaceuticals' 5-year Current Deferred Revenue high stood at $5.1 million for Q4 2015, and its period low was $21,000 during Q2 2015.
  • Over the past 3 years, Avadel Pharmaceuticals' median Current Deferred Revenue value was $1.7 million (recorded in 2018), while the average stood at $1.4 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 97.80% in 2015, then skyrocketed by 18,090.48% in 2016.
  • Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Current Deferred Revenue stood at $5.1 million in 2015, then slumped by 56.59% to $2.2 million in 2016, then fell by 9.72% to $2.0 million in 2017, then plummeted by 94.32% to $114,000 in 2018, then reached $115,000 in 2019.
  • Its Current Deferred Revenue stands at $115,000 for Q1 2019, versus $114,000 for Q4 2018 and $1.7 million for Q3 2018.